Made in USA

Independently verifiedCertified

GLP-3-RT · 30mg

Purity (HPLC)≥98%

LabVantage Analytical

Tested28 Jun 2026

Batch —·

Heavy metalsEndotoxinsMicrobialSolvents

View full COA

In stock

GLP-3-RT

Name: GLP-3-RT
Brand: AXOS
Availability: InStock

$179$5.97/mg

Triple GIP/GLP-1/glucagon receptor agonist — metabolic research reagent

Choose your size

Buy 1, Get 1 Free · auto-applied

Add 2+ items to cart to activate the discount

VISAAMEXPayPal

Secure, encrypted checkout

Independently verifiedCertified

GLP-3-RT · 30mg

Purity (HPLC)≥98%

LabVantage Analytical

Tested28 Jun 2026

Batch —·

Heavy metalsEndotoxinsMicrobialSolvents

View full COA

Frequently bought together

Researchers usually add these to complete the protocol.

BAC Water · 3ml

Essential · Extras

GHK-CU · 50mg

Recovery

$39

Melanotan 2 · 10mg

Tanning

$49

Add all (3)$97

Certificate of analysis

Every vial ships with its own report

We don't publish a brand-wide spec sheet and call it a “COA.” The certificate you receive references the actual lot number stamped on your vial — with the raw chromatograms attached.

Lot-specific HPLC purity + LC-MS identity
Raw chromatogram + mass confirmation attached
Signed off by the lab's Principal Chemist
Permanent archive — searchable by lot ID

View all lab reports

Reference reportView All Live Reports

Vantage Analytical

Independent analytical lab

Certificate of Analysis

RESULT · PASS

ProductGLP-3-RT · 30mg

Lot / batch—

Reported28 Jun 2026

MethodHPLC-UV + LC-MS

AppearanceWhite lyophilized powder

ClientSolace Peptides

Analytical results

Identity (LC-MS)1419.5 DaPASS

Purity (HPLC-UV)≥98%PASS

Net content10.2 mgPASS

Endotoxin (LAL)< 0.05 EU/mgPASS

Heavy metals (ICP-MS)< 10 ppmPASS

Residual solventsBelow LOQPASS

HPLC Chromatogram

Purity ≥98%

Chemist verifiedDr. E. Hartley

Know your compound

What is GLP-3-RT?

GLP-3-RT (generic name: retatrutide) is a synthetic peptide that simultaneously agonises three receptors — GIP, GLP-1, and glucagon — placing it in a distinct compound class from dual incretins. The glucagon receptor arm engages thermogenic and hepatic energy-expenditure pathways not accessible to GLP-1 or GIP alone.

Phase 2 clinical trial data reported the largest reductions in body weight and hepatic fat markers observed to date within the incretin agonist class, drawing substantial investigative attention. Researchers are also studying the compound's simultaneous effects on HbA1c, lipid profiles, and energy expenditure as a multi-axis metabolic model.

Largest body-weight reductions recorded in the incretin agonist class in Phase 2 data
Concurrent improvements in HbA1c, lipid profile, and hepatic fat markers in clinical research
Unique triple-receptor mechanism separates it mechanistically from dual GLP-1/GIP agents

Lot-specific COAEvery lot ships with an HPLC Certificate of Analysis and mass-spectrometry identity confirmation.

Institutional fulfilmentShipped to verified institutional addresses with full analytical documentation.

Lot-specific COA: Every lot ships with an HPLC Certificate of Analysis and mass-spectrometry identity confirmation.
Institutional fulfilment: Shipped to verified institutional addresses with full analytical documentation.

For research use only — not for human or veterinary use.

The research

What the research actually found

The published findings behind this compound — the headline numbers, in plain terms, each cited to source. Preclinical results are directional (animal / in-vitro) and shown for context, not as therapeutic claims.

Published research on the reference compound class. Provided for scientific context only — not a claim about the product supplied.

Weight lossClinical

~24%

In a phase 2 dose-escalation trial (~48 weeks, adults with obesity), participants receiving the highest dose level (48 mg) lost approximately 24% of their body weight on average — among the largest reductions reported in the incretin agonist class to date.

vs lower doses showing graded, smaller reductions

NEJM 2023 · Phase 2 (NCT05019870)

Approximate mean body-weight reductions by dose cohort, Phase 2 trial, ~48 weeks, adults with obesity. Values are relative; display figures are approximate. Source: NEJM 2023.

Blood sugarClinical

Across active dose cohorts in the phase 2 trial, HbA1c — the standard long-term blood-sugar marker — showed a directional decrease relative to placebo, with larger improvements trending toward higher doses. Precise per-cohort figures are pending full phase 3 publication.

vs placebo (directional)

PlaceboBaseline

Active cohortsDirectional ↓

Relative directional change in HbA1c — Phase 2 trial, adults with obesity. No precise per-arm figure is available in published data; bar heights are illustrative of direction only, not a measured magnitude.

NEJM 2023 · Phase 2 (NCT05019870)

Triple vs dual receptorPreclinical

3 vs 2

In vitro receptor-binding assays show GLP-3-RT simultaneously engages three receptors — GIP-R, GLP-1R, and glucagon-R — while dual-incretin agents (e.g. tirzepatide) cover only two, leaving the glucagon-R pathway, linked to hepatic fat clearance and thermogenesis, unactivated.

vs dual GIP-R + GLP-1R agonists (in vitro)

GIP-RGIP-RGLP-1RGLP-1RGlucagon-R (added vs dual)Glucagon-R ✦

Receptor targets engaged in vitro. Glucagon-R (✦) is the pathway absent from dual-incretin comparators. This is a mechanistic characterisation, not a human clinical outcome.

NEJM 2023 · pharmacology characterisation

GLP-1Rincretin axis

GIP-Rincretin potentiation

Glucagon-Renergy expenditure

Mechanism

How GLP-3-RT works

Retatrutide is studied as a simultaneous agonist at three distinct receptors, each engaging a separate biological route relevant to metabolic regulation.

GLP-1Rincretin axis

GLP-1 receptor agonism is studied to enhance glucose-dependent insulin secretion from pancreatic beta-cells, slow gastric emptying, and modulate central satiety signalling in preclinical and clinical models.

GIP-Rincretin potentiation

GIP receptor activation is investigated for its complementary role in potentiating insulin release and, in some model systems, for effects on adipose tissue lipid metabolism and bone turnover distinct from the GLP-1 arm.

Glucagon-Renergy expenditure

Glucagon receptor agonism is studied for its capacity to increase hepatic glucose output, stimulate thermogenesis in brown adipose tissue, and drive energy expenditure — pathways not engaged by incretin-only agonists.

For research use only. Mechanisms described reflect published preclinical and clinical literature.

The process

How every batch is verified

01
Synthesized
Produced under controlled manufacturing with documented, repeatable processes.
02
HPLC purity
An independent lab reports the exact purity of every lot — a number, never a 'passes'.
03
Mass-spec identity
Molecular weight confirms the exact sequence is what the label says.
04
COA published
The certificate is posted to the open library, by lot, before the vial ships.

Verified researchers

Reviewed by people who test it themselves

Best sellers

Researchers reach for these

Best seller

5 Amino 1MQ

50mg

5.0

≥98% HPLC

$89

Best seller

BAC Water

10ml

5.0

$19

BPC-157

10mg

5.0

≥98% HPLC

$69

BPC-157 + TB-500

10mg + 10mg

5.0

≥98% HPLC

$119

CJC / Ipamorelin

5mg + 5mg

5.0

>98% HPLC

$99

CJC-1295 with DAC

5mg

5.0

≥98% HPLC

$79

FAQ

Frequently asked

Common questions about GLP-3-RT

The COA guarantee

≥98% pure — or your money back.

Have any lot independently re-tested. If the results don't match the published certificate, we refund the order in full — no returns, no questions.

Order with cover

Third-party tested

An independent, accredited lab — no commercial interest in the result.

A COA on every lot

A lot-specific certificate ships with each vial, archived by batch.

Test it yourself → refund

Re-test any batch at any lab. A mismatch is a full refund.

Every vial ships with its own report

We don't publish a brand-wide spec sheet and call it a “COA.” The certificate you receive references the actual lot number stamped on your vial — with the raw chromatograms attached.

Lot-specific HPLC purity + LC-MS identity

Raw chromatogram + mass confirmation attached

Signed off by the lab's Principal Chemist

Permanent archive — searchable by lot ID

View all lab reports

What is GLP-3-RT?

Largest body-weight reductions recorded in the incretin agonist class in Phase 2 data

Concurrent improvements in HbA1c, lipid profile, and hepatic fat markers in clinical research

Unique triple-receptor mechanism separates it mechanistically from dual GLP-1/GIP agents

How GLP-3-RT works

Retatrutide is studied as a simultaneous agonist at three distinct receptors, each engaging a separate biological route relevant to metabolic regulation.